Dynavax to Present at Two Focus Sessions at BIO CEO & Investor Conference February 15, 2006
BERKELEY, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present at two focus sessions at the BIO CEO & Investor Conference 2006 at the Waldorf-Astoria Hotel in New York City. Both focus sessions are scheduled for Wednesday, February 15th.
The first focus session is entitled, "TLRs: The Cure for All Ailments" and will take place 8:30 a.m. to 9:55 a.m. Eastern, in the Basildon Room.
The second focus session is entitled, "Vaccines: What is on the Horizon?" and will take place from 3:30 p.m. to 4:55 p.m. Eastern, in the Louis XVI Suite Center/West.
Please visit the BIO CEO & Investor Conference website for information about webcasts of the panel discussions: http://ceo.bio.org/opencms/ceo/2006/program/index.jsp .
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, that has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV™, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.
SOURCE Dynavax Technologies Corporation
02/08/2006
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of
Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com
Web site: http://www.dynavax.com
(DVAX)
02/08/2006 16:07 EST http://www.prnewswire.com